Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professors Stephanie Dakin and Paul Bowness have been announced as 2021 recipients of the Novartis Institutes for BioMedical Research (NIBR) Global Scholars Program (NGSP).

Professors Steph Dakin and Paul Bowness

NGSP is a competitive program designed for innovators from invited institutions to gain funding for breakthrough science that will advance Novartis' mission to improve and extend peoples' lives.

Stephanie Dakin, Associate Professor of Musculoskeletal Sciences at NDORMS joined NGSP to further her research into tendinopathy. She said: "I am delighted and honoured to be recognised as a recipient of the NIBR Global Scholars Program and look forward to establishing a fruitful collaboration with Novartis. This strong collaborative link between academia and pharma provides a unique opportunity to catalyse the development of new therapeutic strategies for tendinopathy treatment."

Paul Bowness, Professor of Experimental Rheumatology will be using his time on the NGSP to focus on finding new ways to understand and treat Spondyloarthritis. "I am excited and honoured to be one of the recipients of 2021 NIBR Global Scholars Program," said Paul. "In collaboration both with Dr Liye Chen at NDORMS and the team at Novartis, we will investigate the scientific mechanisms and therapeutic potential of novel approaches in Spondyloarthritis, a common group of arthritic diseases affecting young people all over the world."

Stephanie and Paul were among five recipients of the program in 2021 and, together with Novartis, they will explore new scientific frontiers in drug discovery and/or clinical research to improve the lives of patients.

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.